- Pfizer and BioNTech announced a new clinical trial for universal COVID-19 vaccine candidates.
- They say the candidates will include T-cell enhancing shots and pan-coronavirus shots that “protect against the broader family of viruses and its mutations.”
- A key challenge for the vaccine is whether or not it will be able to maintain efficacy as the virus mutates.
COVID-19 vaccines wane in efficacy as SARS-CoV-2 mutatesTrusted Source over time. While two doses of an mRNA COVID-19 vaccine were 85% effective in preventing hospital admission for infection with the Alpha and Delta variants of SARS-CoV-2, they were only 65%Trusted Source effective in preventing hospitalization following an Omicron infection.
Source: Medical News Today